Renal transplantationCD26 expression and enzymatic activity in recipients of kidney allografts☆
Section snippets
Materials and methods
We report on the preliminary results of a prospective study with 56 kidney transplant patients within the last 24 months at the Department of General and Thoracic Surgery at the Justus-Liebig-University in Giessen. Directly pretransplantation and before induction therapy, PBL surface expression (FACS, as described elsewhere (2)) of CD26, CD3, CD4, CD8, CD45, CD122, ADA, and serum DPP IV activity (fluorometricaly, as described elsewhere (3) were assessed and monitored. At 1, 7, 14, and 21 days
Results and conclusion
CD26 expression on PBL showed a significant drop from baseline preop (m = 34 ± 18%) for up to 18 months (m = 15.2 ± 11%, P < .001). In contrast, CD4 (decreased expression for 6 months, P < .03), CD8 (for 7 days, P < .0001), CD45 (for 2 months, P = .05), CD3 (for 21 days, P < .01), CD122 (for 21 days, P < .01), and ADA (for 2 months, P < .01) expression kinetics are only briefly affected. In addition, serum DPP IV enzymatic activity was significantly depressed for at least 12 months (m = 85 ±
References (3)
- et al.
Immunology Today
(1999)
Cited by (0)
- ☆
This work was supported by Deutsche Forschungsgemeinschaft grant Ko 1637/2-1.